Ipsen’s Post

NSAIDs and Kidney Function/Disease https://lnkd.in/g5dDAi9p

A research letter published in October 2023 in the Journal of the American Medical Association shows the highly popular GLP-1 agonists for weight loss are facing some safety disadvantages against the established Naltrexone – Bupropion weight loss agent. “Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis (adjusted HR [hazard ratio], 9.09 [95% CI, 1.25-66.00]), bowel obstruction (HR, 4.22 [95% CI, 1.02-17.40]), and gastroparesis (HR, 3.67 [95% CI, 1.15-11.90) but not biliary disease (HR, 1.50 [95% CI, 0.89-2.53]).” As often for medicines, a diversity of therapeutic options brings value to the patients. #naltrexone #API #weightloss

Mindeudesivir Results in the Lancet—Our double-blind, phase 3, placebo-controlled randomized study comparing Mindeudesivir/VV116 (our oral antiviral agent against SARS-CoV-2) with placebo demonstrated that Mindeudesivir significantly reduced the time to sustained clinical symptom resolution compared with placebo. The study’s latest results have been published in the Lancet. A previous active comparator-controlled Phase III study also showed that Mindeudesivir was non-inferior to nirmatrelvir-ritonavir in reducing the time to sustained symptom resolution. Read Paper: https://lnkd.in/eM3Bxjv4 #thelancet #mindeudesivir #vv116 #covid19treatment #clinicaltrialsuccess #innovationinmedicine #junshi #topalliance

Mindeudesivir Results in the Lancet—Our double-blind, phase 3, placebo-controlled randomized study comparing Mindeudesivir/VV116 (our oral antiviral agent against SARS-CoV-2) with placebo demonstrated that Mindeudesivir significantly reduced the time to sustained clinical symptom resolution compared with placebo. The study’s latest results have been published in the Lancet. A previous active comparator-controlled Phase III study also showed that Mindeudesivir was non-inferior to nirmatrelvir-ritonavir in reducing the time to sustained symptom resolution. Read Paper: https://lnkd.in/eM3Bxjv4 #thelancet #mindeudesivir #vv116 #covid19treatment #clinicaltrialsuccess #innovationinmedicine #junshi #topalliance

A study published in American Diabetes Association, led by @Siham AbdElgani at the University of Texas Health Science Center offers hope for millions with fatty liver disease. The research suggests Empagliflozin, a drug used for type 2 diabetes, may reduce liver fat content not just in diabetics, but also in obese individuals without diabetes. This could be a significant advancement in treating metabolic dysfunction-associated steatotic liver disease (MASLD). However, cautious optimism is key. While the study, funded by The National Institutes of Health and supported by Boehringer Ingelheim (Empagliflozin's manufacturer), shows promise, one co-author's financial ties to the pharmaceutical industry necessitates independent replication studies. Additionally, the study's limitations, such as not measuring total body fat oxidation, highlight the need for further research to fully understand Empagliflozin's impact on metabolic health. While this research paves the way for potential future treatments for fatty liver disease, further confirmation and understanding are crucial before definitive conclusions can be drawn. #sentropharma #pharmaindustry #pharmaceuticalindustry #pharmasupplychain #pharmasupplier #medicalcare #fattyliver #obese #diabetescare #metabolichealth #dysfunction

Today’s FDA-approved #obesity medications are primed to become tomorrow’s novel treatments across multidimensional states of disease – from #diabetes to heart failure. In our latest article, nephrologist and Biorasi SAB member, Jamie P. Dwyer, MD, discusses the concept of #diabesitology and the potential of drugs on the #GLP1 axis >> https://bit.ly/3V6CKDm

Our latest #NASHNews is out! 1️⃣ The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST #NASH therapeutic option in the U.S.👏👏👏 2️⃣ Study Reveals Low-Dose #Aspirin to Reduce Hepatic Fat in Patients with #MASLD 3️⃣ Global Fatty Liver Day is on June 13! ⭐️ ...and more of the latest challenges and opportunities that lie in the field of #fattyliverdisease. 🎉 https://lnkd.in/drz-g4-v #LiverHealth #NAFLD #NASH

DrugChatter: Can statins like lipitor affect liver function?

🌟 New article in our Plantrician Library: Understanding GLP-1 Receptor Agonists (Ozempic, Wegovy, and Others)! 🌟 We are thrilled to feature guest author Cyrus Khambatta, PhD! Cyrus is the New York Times bestselling co-author of Mastering Diabetes and has helped more than 10,000 people reverse the underlying cause of insulin resistance. GLP-1 receptor agonists (GLP1-RAs) have gained popularity due to their effectiveness in managing type 2 diabetes and promoting weight loss. Originally developed to reduce blood glucose in type 2 diabetes only, research published in the New England Journal of Medicine documenting the powerful weight loss effects of the active ingredient semaglutide began the movement to prescribe GLP-1 receptor antagonists as an off-label weight-loss drug. While the weight loss effects of GLP-1 RAs are powerful, caution should be exercised when prescribing this class of medications to those trying to lose weight or reduce their blood glucose, due to their extensive list of unwanted side effects. Read more about the research and side effects of GLP-1 RAs here: https://loom.ly/AmZnVyA #plantrician #masteringdiabetes #library #ozempic #wegovy #weightloss #type2diabetes #diabetes #weightlossdrugs #GLP1 #CyrusKhambatta #research

BOXED WARNING FOR DENOSUMAB Based on a completed U.S. Food and Drug Administration (FDA) review of available information, FDA have concluded that the osteoporosis medicine Prolia (denosumab) increases the risk of severe hypocalcemia, very low blood calcium levels, in patients with advanced chronic kidney disease (CKD), particularly patients on dialysis. Severe hypocalcemia appears to be more common in patients with CKD who also have a condition known as mineral and bone disorder (CKD-MBD). In patients with advanced CKD taking Prolia, severe hypocalcemia resulted in serious harm, including hospitalization, life-threatening events, and death. As a result, FDA is revising the Prolia prescribing information to include a new Boxed Warning, FDA’s most prominent warning, communicating this increased risk. Severe hypocalcemia can be asymptomatic or may present with symptoms that include confusion; seizures; irregular heart rhythm; fainting; face twitching; uncontrolled muscle spasms; or weakness, tingling, or numbness in parts of the body.